# LungTIME-C01: HCP commentary report

> 237 verified statements (108 from clinicians verified by NPI or staff page) from 70 commentary sources · 9 findings · updated Oct 30, 2026

## Report

- Trial: Progression Survival Time According to Time-of-Day (ToD) of Administration of Immunochemotherapy for Advanced Non-small Cell Lung Cancer: A Phase III Randomized Control Trial
- NCT ID: NCT05549037
- Registry: https://clinicaltrials.gov/study/NCT05549037
- Sponsor: Hunan Province Tumor Hospital
- Phase: Phase 3
- Status: Completed
- Drugs tested: pembrolizumab; sintilimab
- Indication: advanced non-small cell lung cancer
- Version: v1.0.0, edition 1
- Accepted: 2026-10-30
- Last checked: 2026-10-30
- Release hash: 3368e006dc5fa3868c9b3d58d98bcc6a6086f2e059597e609369d68f25a6ec1a

## Counts

- HCP commentary sources screened: 93
- Sources cited by verified statements: 71
- Verified statements: 237
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 108
- Findings: 9
- Named people in screened sources (unnamed speakers and accounts not counted): 80
- Voices cited: 79
- Cited voices identity-verified: 62
- Organisational or shared accounts (not counted as people): 6

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

Clinician commentary on LungTIME-C01 in the sources reviewed for this edition leads to one open question: How can timing research distinguish a reproducible benefit from protocol, assessment and patient-scheduling effects without delaying access to effective treatment? Its leading findings: (1) retraction limits clinical use of these results without resolving the underlying timing hypothesis. (2) criticism centers on prespecification, protocol chronology and data patterns—not effect-size surprise alone. (3) i-TIMES prompted both timing skepticism and disagreement about what a null interpretation means. 6 more findings follow. 93 sources screened, 71 cited; not all HCPs or all public discussion.

## Open Medical Affairs question

How can timing research distinguish a reproducible benefit from protocol, assessment and patient-scheduling effects without delaying access to effective treatment?

Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. Retraction limits clinical use of these results without resolving the underlying timing hypothesis
- F2. Criticism centers on prespecification, protocol chronology and data patterns—not effect-size surprise alone
- F3. i-TIMES prompted both timing skepticism and disagreement about what a null interpretation means
- F4. Historical adoption views ranged from emphatic practice change to validation-first caution
- F5. Design and generalizability concerns include attribution to ICI versus co-timed chemotherapy
- F6. Circadian immune plausibility coexists with pharmacologic objections and alternative explanations
- F7. Before 15:00 is not synonymous with morning, circadian phase or the timing of every dose
- F8. Cost-neutral treatment is not necessarily cost-neutral service delivery
- F9. Actual scheduling preferences retained exceptions for access, attendance and treatment continuity

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding.

| Finding | Statements | Passages | Sources | Named voices | Counterview | Limitations |
| --- | ---: | ---: | ---: | ---: | --- | ---: |
| F1 | 16 | 18 | 10 | 7 | recorded | 2 |
| F2 | 44 | 27 | 9 | 8 | recorded | 2 |
| F3 | 18 | 21 | 9 | 10 | recorded | 2 |
| F4 | 47 | 43 | 28 | 31 | recorded | 2 |
| F5 | 33 | 28 | 13 | 20 | recorded | 2 |
| F6 | 52 | 51 | 32 | 37 | recorded | 2 |
| F7 | 26 | 24 | 13 | 15 | recorded | 2 |
| F8 | 33 | 34 | 25 | 24 | recorded | 3 |
| F9 | 14 | 14 | 8 | 10 | recorded | 2 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Passages supporting | Passages giving context | Sources by kind | Feeds the Medical Affairs question |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- | --- |
| F1 | 12 | 1 | 0 | 0 | 3 | 19 | 3 | 8 posts and articles, 2 podcasts and video | yes |
| F2 | 32 | 3 | 0 | 4 | 5 | 47 | 10 | 6 posts and articles, 3 podcasts and video | yes |
| F3 | 10 | 2 | 0 | 3 | 3 | 22 | 2 | 8 posts and articles, 1 podcast or video | yes |
| F4 | 35 | 5 | 0 | 1 | 6 | 50 | 1 | 25 posts and articles, 3 podcasts and video | yes |
| F5 | 18 | 11 | 0 | 1 | 3 | 34 | 2 | 11 posts and articles, 2 podcasts and video | yes |
| F6 | 31 | 9 | 0 | 4 | 8 | 55 | 2 | 29 posts and articles, 3 podcasts and video | yes |
| F7 | 11 | 12 | 3 | 0 | 0 | 26 | 1 | 12 posts and articles, 1 podcast or video | yes |
| F8 | 29 | 3 | 0 | 1 | 0 | 34 | 2 | 23 posts and articles, 2 podcasts and video | yes |
| F9 | 8 | 1 | 3 | 0 | 2 | 14 | 1 | 7 posts and articles, 1 podcast or video | yes |

### Trial dimensions

- Primary endpoint: Progression-free survival (PFS): F1 (1 shared claims), F2 (3 shared claims), F4 (22 shared claims), F5 (5 shared claims), F6 (10 shared claims), F7 (3 shared claims), F8 (6 shared claims), F9 (1 shared claims)
- Secondary endpoint: Objective Response Rate (ORR): F4 (5 shared claims), F5 (2 shared claims), F6 (1 shared claims), F8 (2 shared claims)
- Secondary endpoint: Overall survival (OS): F1 (1 shared claims), F2 (1 shared claims), F4 (22 shared claims), F5 (5 shared claims), F6 (11 shared claims), F7 (4 shared claims), F8 (7 shared claims), F9 (1 shared claims)
- Secondary endpoint: Duration of Response (DoR): no finding draws on it directly
- Population and setting: F2 (1 shared claims), F4 (7 shared claims), F5 (14 shared claims), F6 (3 shared claims), F7 (3 shared claims), F8 (5 shared claims), F9 (2 shared claims)
- The comparison: F2 (1 shared claims), F4 (12 shared claims), F5 (9 shared claims), F6 (1 shared claims), F7 (11 shared claims), F8 (9 shared claims), F9 (6 shared claims)
- Safety and tolerability: F2 (3 shared claims), F4 (5 shared claims), F5 (2 shared claims), F6 (9 shared claims), F8 (5 shared claims), F9 (2 shared claims)
- Design and conduct: F1 (4 shared claims), F2 (23 shared claims), F3 (3 shared claims), F4 (13 shared claims), F5 (28 shared claims), F6 (1 shared claims), F7 (4 shared claims), F8 (3 shared claims), F9 (2 shared claims)

## Sample findings

Paraphrased; the full report links each statement to its source.

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 9 | Titles free |
| Detailed analysis | 10 sections | Paid |
| Verified statements with short source quotes and links | 237 | Paid |
| Trial aspects mapped | 14 | Free |
| Sources with links | 71 | Counts free |
| Speaker attribution for cited voices | 79 | Paid |

## Trial aspects

13 discussed · 1 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Progression-free survival (PFS) | discussed | 46 | 37 |
| Secondary endpoint: Objective Response Rate (ORR) | discussed | 9 | 8 |
| Secondary endpoint: Overall survival (OS) | discussed | 45 | 36 |
| Secondary endpoint: Duration of Response (DoR) | no commentary found | 0 | 0 |
| Population and setting | discussed | 21 | 12 |
| The comparison | discussed | 37 | 26 |
| Safety and tolerability | discussed | 20 | 16 |
| Design and conduct | discussed | 56 | 24 |
| Retraction, confidence in the results and clinical usability | discussed | 44 | 15 |
| Conflicting evidence and the i-TIMES comparison | discussed | 21 | 12 |
| Immune biology, pharmacology and alternative temporal explanations | discussed | 58 | 34 |
| Cutoff selection, individual circadian phase and first-dose timing | discussed | 25 | 13 |
| Practical uptake, capacity, delivery route and patient access | discussed | 45 | 27 |
| Scientific prominence, replication priorities and public trust | discussed | 38 | 21 |

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

## Sources

| Channel | Screened | Cited |
| --- | ---: | ---: |
| X threads | 69 | 52 |
| LinkedIn posts | 10 | 10 |
| Bluesky threads | 10 | 4 |
| YouTube | 3 | 3 |
| Podcasts | 1 | 1 |
| Registry (primary source, cited for context) | not screened | 1 |

- Screened window: 2025-05-23 to 2026-10-21
- Cited window: 2025-05-24 to 2026-10-21
- Retrieved: 2026-10-30

Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: Progression Survival Time According to Time-of-Day (ToD) of Administration of Immunochemotherapy for Advanced Non-small Cell Lung Cancer: A Phase III Randomized Control Trial
- Registry: NCT05549037 (https://clinicaltrials.gov/study/NCT05549037)
- Study IDs: INJECTION
- Sponsor: Hunan Province Tumor Hospital
- Design: Phase 3 · interventional, randomized, parallel, phase3
- Status: Completed
- Enrollment: 210 (actual)
- Start: 2022-09-23 (actual)
- Primary completion: 2024-12-02 (actual)
- Primary endpoint: Progression-free survival (PFS) (Time from first subject dose to study completion, or up to 36 month.)
- Intervention: Pembrolizumab, Sintilimab (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- Not yet captured in this edition: a remark on retraction-related uncertainty in the evidence supporting morning cancer-treatment scheduling.
- Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- 44 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits apply, so some matching discussion may be missing.
- The sources reviewed for this edition are not a representative sample of HCP opinion. Search emphasis on the trial identifier and registered names may miss unnamed references or wording variants.
- Forty-four potentially relevant sources without an explicit trial name were not read, and some passages in otherwise reviewed discussions were not fully assessed for clinician views.
- The original results paper, complete protocol and patient-level data were not independently evaluated here. The registry supplies planned methods; numerical results and integrity concerns are attributed reports or interpretations.
- Historical numerical summaries, follow-up durations, assessment descriptions and phase labels differ. They have not been combined into a single corrected efficacy estimate.
- Retraction and editorial concerns do not independently establish fraud, a particular source of bias or exact equivalence between early and late administration.
- Named account identity does not necessarily establish a clinical role. Unverified roles, institutional relays, automated-account commentary and unidentified narration are not counted as additional confirmed HCP perspectives.
- Reposts, duplicated posts and multiple statements by one person do not establish independent corroboration or consensus.
- No matching regulatory document for the combined registry intervention entry was available. Suggestions involving subcutaneous or home administration do not establish approval, equivalence or administration requirements.
- No substantive commentary on duration of response was identified in the material reviewed.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, accepted 2026-10-30: current edition

Last checked for new commentary 2026-10-30. No corrections. Versions follow semver: a new or changed finding is a minor version, more evidence without a material change is a patch.

## Offer

- Size: Standard (237 verified statements)
- Current edition: $1,250. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of weekly updates: $2,200
- 6 months of weekly updates: $3,100
- 12 months of weekly updates: $4,400
- Optional identity linkages (12-month updates only, product updates-12-identities; speakers are named and described in every report): NPI and other verified IDs at $15 per identity-verified person in the edition at purchase (62 now), at most $1,250; people verified later in the term at no charge
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/lungtime-c01-nct05549037
- Agents: POST https://www.erudio.com/api/orders with {"report": "lungtime-c01-nct05549037", "product": "edition" | "updates-3" | "updates-6" | "updates-12" | "updates-12-identities", "buyer_email": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=lungtime-c01-05549037

## Cite

Erudio Health. LungTIME-C01 (NCT05549037): HCP commentary report. Edition 1, v1.0.0. Accepted Oct 30, 2026. https://www.erudio.com/reports/lungtime-c01-nct05549037

## Machine access

- JSON: https://www.erudio.com/reports/lungtime-c01-nct05549037.json
- Markdown: https://www.erudio.com/reports/lungtime-c01-nct05549037.md
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "lungtime-c01-05549037"}`